Research programme - autologous stem cell therapies - ProteonomixAlternative Names: StromaCel
Latest Information Update: 12 Oct 2012
At a glance
- Originator Proteonomix; StromaCel
- Class Stem cell therapies
- Mechanism of Action Cell replacements; Pancreatic beta cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Type 1 diabetes mellitus
- Research Myocardial infarction